



University of Dundee

Development of Simplified Heterocyclic Acetogenin Analogues as Potent and Selective *Trypanosoma brucei* Inhibitors

Florence, Gordon J.; Fraser, Andrew L.; Gould, Eoin R.; King, Elizabeth F.; Menzies, Stefanie K.; Morris, Joanne C.

Published in:
ChemMedChem

DOI:
[10.1002/cmdc.201600210](https://doi.org/10.1002/cmdc.201600210)

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Florence, G. J., Fraser, A. L., Gould, E. R., King, E. F., Menzies, S. K., Morris, J. C., ... Smith, T. K. (2016). Development of Simplified Heterocyclic Acetogenin Analogues as Potent and Selective *Trypanosoma brucei* Inhibitors. *ChemMedChem*, 11(14), 1503-1506. <https://doi.org/10.1002/cmdc.201600210>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Development of Simplified Heterocyclic Acetogenin Analogues as Potent and Selective *Trypanosoma brucei* Inhibitors

Gordon J. Florence,* Andrew L. Fraser, Eoin R. Gould, Elizabeth F. King, Stefanie K. Menzies, Joanne C. Morris, Marie I. Thomson, Lindsay B. Tulloch, Marija K. Zacharova, and Terry K. Smith^[a]

Neglected tropical diseases caused by parasitic infections are an ongoing and increasing concern. They are a burden to human and animal health, having the most devastating effect on the world's poorest countries. Building upon our previously reported triazole analogues, in this study we describe the synthesis and biological testing of other novel heterocyclic acetogenin-inspired derivatives, namely 3,5-isoxazoles, furoxans, and furazans. Several of these compounds maintain low-micromolar levels of inhibition against *Trypanosoma brucei*, whilst having no observable inhibitory effect on mammalian cells, leading to the possibility of novel lead compounds for selective treatment.

Neglected tropical diseases remain one of the largest concerns in the developing countries of Africa and the South Americas, both in terms of healthcare provision and financial impact on the economies of the world's poorest countries. This ongoing threat has arisen from a lack of effective prevention methods and minimal financial incentive to develop new therapeutic agents.^[1] One of these prevalent neglected tropical diseases which has attracted attention in recent years is African sleeping sickness or human African trypanosomiasis (HAT), caused by the protozoan parasite *Trypanosoma brucei*. HAT is a serious health concern in sub-Saharan Africa with >65 million people at risk and with an annual mortality rate of approximately 9000 per annum.^[2] The World Health Organization (WHO) estimates 20 000 new cases of HAT per year based on reported cases, and has set an ambitious target to eradicate HAT by 2020.^[3] Current drug treatments depend on the stage of HAT and are difficult to administer to patients, requiring lengthy infusion rates, and have varying degrees of human toxicity, while showing low efficacy toward the parasite.^[4] The combination

eflornithine/nifurtimox therapy (NECT) for stage 2 HAT has proven successful, but resistance to this combination therapy is emerging.^[5] The lack of new effective therapeutic agents and the onset of drug resistance highlights the urgent need for the development of novel small molecule inhibitors of *T. brucei* as potential lead compounds in the quest for new and effective treatments for HAT.^[6]

Acetogenins are a class of polyketide secondary metabolites isolated from medicinal plants of the *Annonaceae* species, typically found in tropical regions of West Africa and South America.^[7,8] Isolated in 2004 by Laurens et al. from the roots of bush banana plant *Uvaria chamae*, chamuvarinin **1**, displayed high levels of cytotoxicity toward the KB3-1 cell line (IC₅₀ = 0.8 nM).^[9] In 2011, our research group reported the first total synthesis of this unique tetrahydropyran-containing acetogenin and found **1** to exhibit unexpected trypanocidal activity in both the bloodstream and procyclic forms of *T. brucei* (Figure 1).^[10,11] Inspired by chamuvarinin, we sought to design a series of simplified acetogenin-like analogues retaining key structural and stereochemical features of the parent natural product. These simplified analogues were assembled from a pool of readily accessible chiral tetrahydropyran (THP) building blocks via copper-mediated click chemistry.^[12] These 1,4-triazole linked analogues, including **2**, maintained high trypanocidal activity with modest selectivity profiles when compared against the human HeLa cell line.

Following on from this success we sought to explore alternative heterocyclic linkers, in particular those that would directly attach the heterocycle spacer to the flanking THP rings, in close analogy to the acetogenins. This direct linkage serves to decrease the molecules' available degrees of freedom and so potentially improve binding efficiency. Moreover, we wished to expand the toolbox of available reactions employing our chiral THP building blocks as a source of molecular diversity. This paper describes the expansion of our methodology to new heterocycles: 3,5-isoxazoles, furoxans and furazans, as well as their assessment as potential trypanocidal agents.

Despite their prevalence in natural products and their presence in several important drug compounds (e.g., valdecoxib, leflunomide, cloxacillin),^[13] synthetic routes to aliphatic isoxazoles remain extremely limited.^[14] In particular, there are only limited examples of α -oxygenated 3,5-isoxazoles and none of these, to our knowledge, have been prepared in enantio-enriched form. Our approach employs the coupling of chiral α -oxygenated alkynes with in situ prepared nitrile oxides, derived

[a] Dr. G. J. Florence, A. L. Fraser, Dr. E. R. Gould, E. F. King, S. K. Menzies, Dr. J. C. Morris, M. I. Thomson, Dr. L. B. Tulloch, M. K. Zacharova, Prof. Dr. T. K. Smith
EaStCHEM School of Chemistry and School of Biology,
Biomedical Sciences Research Complex,
University of St. Andrews, North Haugh, St. Andrews, KY16 9ST, (UK)
E-mail: gjf1@st-andrews.ac.uk

Supporting information for this article can be found under <http://dx.doi.org/10.1002/cmdc.201600210>.

© 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.





Figure 1. Rationale of new *T. brucei* inhibitors inspired by acetogenins.

from the corresponding oximes, in a [3+2] cycloaddition. Oximes 3–5 were rapidly accessed from the corresponding THP alcohols by Swern oxidation and condensation with hy-



Scheme 1. Synthesis of oximes 3–5: a) $(\text{COCl})_2$, DMSO, CH_2Cl_2 , Et_3N , $-78^\circ\text{C} \rightarrow \text{RT}$; b) $\text{NH}_2\text{OH}\cdot\text{HCl}$, EtOH , $0^\circ\text{C} \rightarrow \text{RT}$.

droxylamine (Scheme 1). Synthesis of the required alkyne-substituted THP precursors 6–8 have been previously described.^[10,12]

A screen of isoxazole-forming reaction conditions, focused on the choice of oxidising agent (required to generate the nitrile oxide) found that *tert*-butylhypochlorite was essential as the oxidising agent.^[15,16] These conditions were successfully applied across a range of substrates with varying side-chain substitution and THP stereochemistry giving isoxazoles 9–13 (Scheme 2). Yields were generally modest, but nonetheless rapidly generated sufficient quantities of these synthetically demanding substrates for biological evaluation.

Screening results for our compounds against procyclic and bloodstream forms of *T. brucei* are outlined in Table 1. Also included are the results of HeLa cell line screening which we have employed as a repre-

sentative human cell line to assess our analogues' selectivity. In general, the isoxazole motif was well tolerated with comparable activity toward *T. brucei* being maintained to the original triazole analogues. The THP stereochemistry had a significant influence on potency with the *syn-syn* compounds 9 and 10 and *anti-anti* 13 most potent. This is in contrast to our original triazole series where *anti-anti* analogues were generally inactive.^[12] Of particular interest were the good levels of selectivity displayed across


the series against *T. brucei* over mammalian HeLa cells, with all but one of the analogues greater than $100\ \mu\text{M}$ against HeLa cells.

In the preparation of the isoxazole analogues, we identified significant by-product formation—namely the furoxan arising from nitrile oxide dimerisation.^[17] These could be isolated in trace amounts but were more productively generated by simply warming the reaction after nitrile oxide formation in


Table 1. Biological data for isoxazoles 9–13.

Entry	Analogue	EC_{50} [μM]			$\text{SI}^{[a]}$
		<i>T. brucei</i> (BSF)	<i>T. brucei</i> (insect)	HeLa	
1	9: R = Et 10: R = OBn	4.5 ± 0.2	19.6 ± 3.1	107.8 ± 4.9	24
2	11	9.0 ± 0.6	43.8 ± 4.0	> 200	> 22
3	12	30.9 ± 1.4	69.3 ± 5.1	> 200	> 6.5
4	13	17.4 ± 0.5	> 60	68.8 ± 6.8	4.0
5	13	5.6 ± 0.2	16.6 ± 2.2	> 100	> 18

[a] Selectivity index: $(\text{EC}_{50} \text{ HeLa})/(\text{EC}_{50} \text{ T. brucei})$.



Scheme 2. Synthesis of isoxazoles **9–13**: a) $t\text{BuOCl}$ then Et_3N , $-78^\circ\text{C} \rightarrow \text{RT}$.



Scheme 3. Synthesis of furoxans **14–16** and furazans **17–19**: a) $t\text{BuOCl}$ then Et_3N , $-78^\circ\text{C} \rightarrow \text{RT}$; b) $\text{P}(\text{OEt})_3$, reflux.

order to induce dimerisation (in the absence of alkyne). This generated furoxans **14–16** in useful quantities (Scheme 3). While interesting in their own right, these compounds also allowed rapid access to furazans **17–19** by simple reduction with triethyl phosphite.

Screening of these compounds revealed that furoxans also displayed encouraging *T. brucei* activity with *anti-anti* analogue **15** most potent and 5.6 times more selective over HeLa cells (Table 2, entry 2).^[18] Pleasingly, select furazan compounds maintain good *T. brucei* inhibition, while being essentially inactive toward HeLa (**18**, >44-fold selectivity, entry 5). The selectivity observed in this instance merits further detailed study of this unusual heterocyclic framework.

We have demonstrated the utility of our chiral THP building blocks by their elaboration to oximes and their use in ‘Click’ re-

actions with alkynes to generate complex isoxazole products. Moreover, dimerisation of these oximes allows access to furoxan and furazan heterocycles. All series tested show encouraging low micromolar activity in *T. brucei* and excellent selectivity over mammalian cells in certain cases. These selectivities are a significant improvement over our previously described triazole compounds and can serve as a basis for further optimisation. Current efforts are focused on other heterocyclic spacers as well as the synthesis of fluorescent and affinity tagged versions in order to isolate target protein(s) allowing us to establish the trypanocidal mode of action.

Table 2. Biological data for furoxans 14–16 and furazans 17–19.

Entry	Analogue	EC ₅₀ [μM]			S ^[a]
		<i>T. brucei</i> (BSF)	<i>T. brucei</i> (insect)	HeLa	
1	14	8.7 ± 0.4	> 50	66.6 ± 6.8	7.7
2	15	4.5 ± 0.3	5.5 ± 0.2	25.4 ± 12.6	5.6
3	16	63.8 ± 5.3	> 500	> 500	> 7.8
4	17	16.3 ± 0.5	26.6 ± 1.9	142.9 ± 17.3	8.8
5	18	11.3 ± 0.6	> 100	> 500	> 44
6	19	146 ± 7.7	> 500	> 500	> 3.4

[a] Selectivity index: (EC₅₀ HeLa)/(EC₅₀ *T. brucei*).

Acknowledgements

This work was funded by the Leverhulme Trust (G.J.F.), and the Wellcome Trust (T.K.S., WT 093228). We thank the EPSRC National Mass Spectrometry Service Centre, Swansea, UK for mass spectrometry services.

Keywords: [3 + 2] cycloaddition · drug discovery · natural product analogues · trypanosomatids

- [1] L. Zhou, G. Stewart, E. Rideau, N. J. Westwood, T. K. Smith, *J. Med. Chem.* **2013**, *56*, 796–806.
 [2] R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyan et al., *Lancet* **2012**, *380*, 2095–2128.
 [3] *Trypanosomiasis, African*, World Health Organization, Geneva, **2016**, www.who.int/topics/trypanosomiasis_african/en/ (accessed April 7, 2016).
 [4] a) D. Steverding, *Parasites Vectors* **2010**, *3*, 15; b) V. Delespau, H. P. de Koning, *Drug Resist. Updates* **2007**, *10*, 30–50.
 [5] G. Priotto, S. Kasparian, W. Mutombo, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, E. Baudin, V. Buard, S. Kazadi-Kyanza, M. Ilunga, W.

- Mutangala, G. Pohlig, C. Schmid, U. Karunakara, E. Torreele, V. Kande, *Lancet* **2009**, *374*, 56–64.
 [6] a) P. M. Njogu, E. M. Guantai, E. Pavadai, K. Chibale, *ACS Infect. Dis.* **2016**, *2*, 8–31; b) A. S. Nagle, S. Khare, A. B. Kumar, F. Supek, A. Buchynskyy, C. J. N. Mathison, N. K. Chennamaneni, N. Pendem, F. S. Buckner, M. H. Gelb, V. Molteni, *Chem. Rev.* **2014**, *114*, 11305–11347.
 [7] a) F. Q. Alali, X. X. Liu, J. L. McLaughlin, *J. Nat. Prod.* **1999**, *62*, 504–540; b) M. C. Zafra-Polo, B. Figadère, T. Gallardo, J. R. Tormo, D. Cortes, *Phytochemistry* **1998**, *48*, 1087–1117; c) M. C. Zafra-Polo, M. C. González, E. Estornell, S. Sahpaz, D. Cortes, *Phytochemistry* **1996**, *42*, 253–271; d) L. Zeng, Q. Ye, N. H. Oberlies, G. Shi, Z. M. Gu, K. He, J. L. McLaughlin, *Nat. Prod. Rep.* **1996**, *13*, 275–306; e) J. K. Rupprecht, Y. H. Hui, J. L. McLaughlin, *J. Nat. Prod.* **1990**, *53*, 237–278.
 [8] A. Bermejo, B. Figadère, M. C. Zafra-Polo, I. Barrachina, E. Estornell, D. Cortes, *Nat. Prod. Rep.* **2005**, *22*, 269–303.
 [9] a) D. Fall, R. A. Duval, C. Gleye, A. Laurens, R. Hocquemiller, J. Nat. Prod. **2004**, *67*, 1041–1043; b) S. Derbré, E. Poupon, C. Gleye, R. Hocquemiller, *J. Nat. Prod.* **2007**, *70*, 300–303.
 [10] a) G. J. Florence, J. C. Morris, R. G. Murray, J. D. Osler, R. R. Vanga, T. K. Smith, *Org. Lett.* **2011**, *13*, 514–517; b) G. J. Florence, J. C. Morris, R. G. Murray, R. R. Vanga, J. D. Osler, T. K. Smith, *Chem. Eur. J.* **2013**, *19*, 8309–8320.
 [11] For investigations into the trypanocidal activity of the acetogenins, see: a) S. Sahpaz, C. Bories, P. M. Loiseau, D. Cortès, R. Hocquemiller, A. Laurens, A. Cavé, *Planta Med.* **1994**, *60*, 538–540; b) A. I. Waechter, G. Yaluff, A. Inchausti, A. Rojas de Arias, R. Hocquemiller, A. Cavé, A. Fournet, *Phytother. Res.* **1998**, *12*, 541; c) S. Hoet, F. Opperdoes, R. Brun, J. Quetin-Leclercq, *Nat. Prod. Rep.* **2004**, *21*, 353–364.
 [12] G. J. Florence, A. L. Fraser, E. R. Gould, E. F. King, S. K. Menzies, J. C. Morris, L. B. Tulloch, T. K. Smith, *ChemMedChem* **2014**, *9*, 2548–2556.
 [13] A. I. Kotyatkina, V. N. Zhabinsky, V. A. Khripach, *Russ. Chem. Rev.* **2001**, *70*, 641–653.
 [14] a) F. Hu, M. Szostak, *Adv. Synth. Catal.* **2015**, *357*, 2583–2614; b) M. Benlifa, S. Vidal, B. Fenet, M. Msaddek, P. G. Goekjian, J. P. Praly, A. Brunyánszki, T. Docsa, P. Gergely, *Eur. J. Org. Chem.* **2006**, 4242–4256; c) R. O. Gould, K. E. McGhie, R. M. Paton, *Carbohydr. Res.* **1999**, *322*, 1–13; d) K. V. Gothelf, K. A. Jørgensen, *Chem. Rev.* **1998**, *98*, 863–909.
 [15] A variety of oxidising agents were screened without success, namely NaOCl, NCS, PIFA, Chloramine-T.
 [16] J. W. Bode, E. M. Carreira, *J. Am. Chem. Soc.* **2001**, *123*, 3611–3612.
 [17] J. Boström, A. Hogner, A. Llinàs, E. Wellner, A. T. Plowright, *J. Med. Chem.* **2012**, *55*, 1817–1830.
 [18] S. D. Jorge, M. Ishii, F. Palace-Berl, A. K. Ferreira, P. L. de Sá Júnior, A. A. de Oliveira, I. Y. Sonehara, K. F. M. Pasqualoto, L. C. Tavares, *MedChemComm* **2012**, *3*, 824–828.

Received: April 18, 2016

Revised: May 19, 2016

Published online on June 10, 2016